Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 376

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 376
---
, failure to respond to official actions within prescribed time limits, non-payment of fees
and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications
covering our product candidates or any future product candidate, our competitors might be able to enter the market earlier than anticipated,
which would have an adverse effect on our business.

Third party claims or litigation alleging infringement, misappropriation
or other violations of third-party patents or other proprietary rights or seeking to invalidate our patents or other proprietary
rights, may delay or prevent the development and commercialization of our product candidates and any future product candidate.

Our commercial success depends in part on our avoidance of infringement,
misappropriation and other violations of the patents and proprietary rights of third parties. However, our research, development and
commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual
property rights owned or controlled by third parties. Our competitors or other third parties may assert infringement claims against us,
alleging that our product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that
we will not infringe patents that may be granted in the future. There is a substantial amount of litigation, both within and outside
the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including
patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review, and
post-grant review before the USPTO, as well as oppositions and similar processes in other jurisdictions. Numerous U.S. and non-U.S. issued
patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are
developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain
greater visibility, the risk increases that our product candidates or other business activities may be subject to claims of infringement
of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing
their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.

71

Additionally, because patent applications can take many years
to issue, there may be currently pending patent